Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：162頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014’, provides an overview of the Gastrointestinal Stromal Tumor (GIST)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014’, provides an overview of the Gastrointestinal Stromal Tumor (GIST)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Gastrointestinal Stromal Tumor (GIST) Overview 9
Therapeutics Development 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 11
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 12
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 14
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 20
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 21
Eli Lilly and Company 21
Novartis AG 22
Astellas Pharma Inc. 23
Astex Pharmaceuticals, Inc. 24
Bayer AG 25
Ariad Pharmaceuticals, Inc. 26
Threshold Pharmaceuticals, Inc. 27
Synta Pharmaceuticals Corp. 28
Chipscreen Biosciences Ltd 29
Ambit Biosciences Corporation 30
Deciphera Pharmaceuticals, LLC 31
Xcovery, Inc. 32
AB Science 33
Clovis Oncology, Inc. 34
EirGen Pharma Ltd. 35
AROG Pharmaceuticals LLC 36
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
regorafenib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
masitinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
nilotinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
masitinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
olaratumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
linsitinib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ponatinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AT-13387 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ganetespib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dovitinib lactate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
crenolanib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
luminespib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MEK-162 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TH-302 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
buparlisib hydrochloride - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CS-2164 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Mixed Bacterial Vaccine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
X-82 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
quizartinib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
DCC-2618 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Mutant cKIT Inhibitor - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Drug Targeting c-Kit - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Eir-108 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates 100
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 150
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 151
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 152
Featured News & Press Releases 152
Oct 18, 2013: Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours, A Rare Form Of Sarcoma 152
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 153
Sep 12, 2013: Bayer to Present Data on Regorafenib at the European Cancer Congress 2013 154
Sep 05, 2013: Bayer’s Regorafenib Submitted for European Marketing Authorization for the Treatment of Gastrointestinal Stromal Tumors 155
Aug 20, 2013: Bayer’s Stivarga Approved for the Treatment of Patients with Gastrointestinal Stromal Tumors in Japan 156
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 156
Jun 04, 2013: IPAB Sets Aside Patent Revocation Order On Pfizer's Anti-Cancer Drug Sutent 157
Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 157
May 15, 2013: Onyx Pharma Announces Data Presentations On Stivarga At 49th American Society Of Clinical Oncology Annual Meeting 159
Apr 11, 2013: IPAB Issues Stay On Revocation Of Pfizer's Sutent Patent 160
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 162
Disclaimer 162
List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2014 10
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Comparative Analysis by Unknown Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Company, H1 2014 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2014 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astellas Pharma Inc., H1 2014 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H1 2014 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2014 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ambit Biosciences Corporation, H1 2014 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Xcovery, Inc., H1 2014 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science, H1 2014 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Clovis Oncology, Inc., H1 2014 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by EirGen Pharma Ltd., H1 2014 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AROG Pharmaceuticals LLC, H1 2014 36
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H1 2014 100
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2014 150
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2014 151
List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2014 10
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Gastrointestinal Stromal Tumor (GIST) Overview 9
Therapeutics Development 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 10
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 11
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 12
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 14
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 20
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 21
Eli Lilly and Company 21
Novartis AG 22
Astellas Pharma Inc. 23
Astex Pharmaceuticals, Inc. 24
Bayer AG 25
Ariad Pharmaceuticals, Inc. 26
Threshold Pharmaceuticals, Inc. 27
Synta Pharmaceuticals Corp. 28
Chipscreen Biosciences Ltd 29
Ambit Biosciences Corporation 30
Deciphera Pharmaceuticals, LLC 31
Xcovery, Inc. 32
AB Science 33
Clovis Oncology, Inc. 34
EirGen Pharma Ltd. 35
AROG Pharmaceuticals LLC 36
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
regorafenib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
masitinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
nilotinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
masitinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
olaratumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
linsitinib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ponatinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AT-13387 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ganetespib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
dovitinib lactate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
crenolanib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
luminespib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MEK-162 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TH-302 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
buparlisib hydrochloride - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CS-2164 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Mixed Bacterial Vaccine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
X-82 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
quizartinib - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
DCC-2618 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Mutant cKIT Inhibitor - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Drug Targeting c-Kit - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Eir-108 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates 100
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 150
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 151
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 152
Featured News & Press Releases 152
Oct 18, 2013: Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours, A Rare Form Of Sarcoma 152
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 153
Sep 12, 2013: Bayer to Present Data on Regorafenib at the European Cancer Congress 2013 154
Sep 05, 2013: Bayer’s Regorafenib Submitted for European Marketing Authorization for the Treatment of Gastrointestinal Stromal Tumors 155
Aug 20, 2013: Bayer’s Stivarga Approved for the Treatment of Patients with Gastrointestinal Stromal Tumors in Japan 156
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 156
Jun 04, 2013: IPAB Sets Aside Patent Revocation Order On Pfizer's Anti-Cancer Drug Sutent 157
Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 157
May 15, 2013: Onyx Pharma Announces Data Presentations On Stivarga At 49th American Society Of Clinical Oncology Annual Meeting 159
Apr 11, 2013: IPAB Issues Stay On Revocation Of Pfizer's Sutent Patent 160
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 162
Disclaimer 162
List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2014 10
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Comparative Analysis by Unknown Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Company, H1 2014 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2014 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astellas Pharma Inc., H1 2014 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H1 2014 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2014 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ambit Biosciences Corporation, H1 2014 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Xcovery, Inc., H1 2014 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science, H1 2014 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Clovis Oncology, Inc., H1 2014 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by EirGen Pharma Ltd., H1 2014 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AROG Pharmaceuticals LLC, H1 2014 36
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H1 2014 100
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2014 150
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2014 151
List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2014 10
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47
